Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA075456-04A1
Application #
6383911
Study Section
Radiation Study Section (RAD)
Program Officer
Stone, Helen B
Project Start
1997-08-01
Project End
2006-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
4
Fiscal Year
2001
Total Cost
$261,595
Indirect Cost

  Institution

Name
Henry Ford Health System
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202

  Publications

Barton, Kenneth N; Xia, Xueqing; Yan, Hui et al. (2004) A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors. Mol Ther 9:625-31
Barton, Kenneth N; Tyson, Donald; Stricker, Hans et al. (2003) GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 8:508-18
Freytag, Svend O; Stricker, Hans; Pegg, Jan et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63:7497-506
Freytag, Svend O; Paielli, Dell; Wing, Mark et al. (2002) Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54:873-85
Freytag, Svend O; Khil, Mark; Stricker, Hans et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62:4968-76
Paielli, D L; Wing, M S; Rogulski, K R et al. (2000) Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 1:263-74
Rogulski, K R; Freytag, S O; Zhang, K et al. (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60:1193-6
Rogulski, K R; Wing, M S; Paielli, D L et al. (2000) Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11:67-76
Xie, Y; Gilbert, J D; Kim, J H et al. (1999) Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res 5:4224-32
Freytag, S O; Rogulski, K R; Paielli, D L et al. (1998) A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9:1323-33